Biocon Biologics Ltd on Friday signed a Distribution Agreement with Sandoz, granting the Company the exclusive rights to promote, sell and distribute th injection of Adalimumab BS in Japan.
“Based on this Agreement, Viatris has completed marketing and promotion of the product as of December 15, 2023, but will continue to provide transition support until Sandoz will gradually assume responsibilities for the product starting February 15, 2024. Biocon Biologics has acquired the global biosimilars portfolio of Viatris including Adalimumab. Fujifilm Kyowa Kirin Biologics Co. Ltd., the developer of the drug, has concluded an exclusive global marketing license agreement with Biocon Biologics Ltd affiliate,” the company said in a statement.
Adalimumab BS for subcutaneous injection [FKB] is a biosimilar of Humira (generic name: adalimumab (genetical recombination)) and is indicated for immune-related diseases such as rheumatoid arthritis, psoriasis vulgaris, ankylosing spondylitis, Crohn’s disease, and ulcerative colitis.
“Sandoz is committed to further strengthening its product pipeline to drive sustainable business growth,” it added.
The transfer of the distribution rights of this product is part of this strategy, and its addition to the product portfolio will strengthen Sandoz’s immunology and biosimilar portfolio.
Biocon Biologics recently announced the successful completion of its integration of the acquired Viatris’ biosimilars business in 120 countries ahead of schedule, marking a significant milestone in the Company’s journey as a fully integrated, global biosimilars enterprise. At a global level, Biocon Biologics has a robust pipeline of 20 assets for diabetology, oncology, immunology, and ophthalmology.
